Home » NOVARTIS' TASIGNA SHOWS POSITIVE RESULTS IN TRIAL
NOVARTIS' TASIGNA SHOWS POSITIVE RESULTS IN TRIAL
Swiss drugmaker Novartis' investigational drug Tasigna helped more than 90 percent of patients diagnosed with an unresponsive form of leukemia, according to a clinical trial published in the New England Journal of Medicine.
In the study, Tasigna compound helped 92 percent of patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia achieve a complete hematologic response with normal white blood cell counts after five months, the company said.
This form of leukemia was treatment-resistant, with the patients previously showing resistant or intolerant to treatment with another Novartis drug, Gleevec.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May